[Advances in the treatment of scleroderma].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D006974:Hypertension, Malignant / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology; D011658:Pulmonary Fibrosis / Q000209:etiology; D011928:Raynaud Disease / Q000209:etiology; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D014665:Vasodilator Agents
Avances en el tratamiento de la esclerodermia.